JPRN-C000000408未知2 期
Gefitnib monotherapy in patients with post-operative recurrent non-small-cell lung cancer with the EGFR mutation: a Phase II study - Gefitnib monotherapy in patients with post-operative recurrent non-small-cell lung cancer with the EGFR mutation: a Phase II study
Okayama University Cancer and Thoracic Surgery0 个研究点目标入组 40 人开始时间: 2006年4月24日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)EGFR mutations except exon19 deletion and exon21 mutation (L858R) or double mutation. 2)Serious infectious disease 3) Brain metastases requiring treatment 4) Serious concomitant disease 5) Ascites, pleural or pericardeal effusion requiring drainage 6)Pregnant or lactation women, or women with known or suspected pregnancy 7) Apparent ineterstitial pneumonia or pulmonary fibrosis 8) Prior treatment of gefitinib 9) Requiring emergency radiotherapy Cardiac infarction within 6 month 10)Inappropriate patients for this study judged by the physicians
研究者
相似试验
已完成
不适用
Phase I/II study of Gefitnib monotherapy as neo-adjuvant chemotherapy for cN2 lung adenocarcinoma with the EGFR mutatioJPRN-UMIN000004807KantoKoshinetsu lung cancer research group20
已完成
不适用
Clinical study of a combined use of Gefitinib and autologous lymphocyte-activated killer cells (LAK) therapy for advanced non-small cell lung cancer.non-small cell lung cancerJPRN-UMIN000000637Juntendo University, School of Medicine20
已完成
2 期
A Phase II Study of Gefitinib Monotherapy as First-Line Treatment for Elderly Patients with Stage IIIB /IV Adenocarcinoma of the LungJPRN-UMIN000006144Central Japan Lung Study Group32
已完成
2 期
Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC)Carcinoma, Non-Small-Cell LungNCT00824746Chonnam National University Hospital23
招募中
不适用
Efficacy and safety of gefitinib monotherapy for all types of refractory cancer patients with EGFR amplificatioKCT0004066Samsung Medical Center3